Lidocaine hydrochloride - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for lidocaine hydrochloride and what is the scope of patent protection?
Lidocaine hydrochloride
is the generic ingredient in thirty-five branded drugs marketed by Thea Pharma, Carlisle, Abbott, Abraxis Pharm, Afaxys, Am Regent, Aspiro, B Braun Medical Inc, Bel Mar, Belmora Llc, Dell Labs, Elkins Sinn, Epic Pharma Llc, Eugia Pharma, Fresenius Kabi Usa, Gd Searle Llc, Hospira, Huons, Intl Medication, Luitpold, Lyphomed, Mankind Pharma, Miles, Rising, Sintetica Us, Spectra Mdcl Devices, Watson Labs, West-ward Pharms Int, Wyeth Ayerst, Baxter Hlthcare, B Braun, Mylan Labs Ltd, Pharmaton, Meridian Medcl Techn, Astrazeneca, Dentsply Pharm, Bionpharma, Sagent Pharms Inc, Cosette, Sentiss, Watson Labs Inc, Hikma, Rubicon, Wockhardt Bio Ag, Actavis Mid Atlantic, Chartwell Molecular, Pai Holdings Pharm, Kendall Il, Lannett Co Inc, Novitium Pharma, Paco, Taro, Powder Pharms, and Pfizer, and is included in one hundred and thirteen NDAs. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.Lidocaine hydrochloride has nineteen patent family members in ten countries.
There are nine drug master file entries for lidocaine hydrochloride. Fifty suppliers are listed for this compound.
Summary for lidocaine hydrochloride
| International Patents: | 19 |
| US Patents: | 4 |
| Tradenames: | 35 |
| Applicants: | 54 |
| NDAs: | 113 |
| Drug Master File Entries: | 9 |
| Finished Product Suppliers / Packagers: | 50 |
| Raw Ingredient (Bulk) Api Vendors: | 67 |
| Clinical Trials: | 1,780 |
| Patent Applications: | 5 |
| Formulation / Manufacturing: | see details |
| What excipients (inactive ingredients) are in lidocaine hydrochloride? | lidocaine hydrochloride excipients list |
| DailyMed Link: | lidocaine hydrochloride at DailyMed |
Recent Clinical Trials for lidocaine hydrochloride
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Arkansas Children's Hospital Research Institute | Phase 4 |
| Universitas Sebelas Maret | Phase 4 |
| Indonesia Endowment Fund for Education | Phase 4 |
Pharmacology for lidocaine hydrochloride
| Drug Class | Amide Local Anesthetic Antiarrhythmic Catecholamine alpha-Adrenergic Agonist beta-Adrenergic Agonist |
| Mechanism of Action | Adrenergic alpha-Agonists Adrenergic beta-Agonists |
| Physiological Effect | Local Anesthesia |
US Patents and Regulatory Information for lidocaine hydrochloride
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Actavis Mid Atlantic | LIDOCAINE HYDROCHLORIDE VISCOUS | lidocaine hydrochloride | SOLUTION;ORAL | 086578-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Mankind Pharma | LIDOCAINE HYDROCHLORIDE | lidocaine hydrochloride | INJECTABLE;INJECTION | 217693-001 | Jul 11, 2023 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Miles | LIDOCAINE HYDROCHLORIDE | lidocaine hydrochloride | INJECTABLE;INJECTION | 080414-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Fresenius Kabi Usa | XYLOCAINE | lidocaine hydrochloride | INJECTABLE;INJECTION | 006488-007 | Approved Prior to Jan 1, 1982 | AP | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Hospira | LIDOCAINE HYDROCHLORIDE | lidocaine hydrochloride | INJECTABLE;INJECTION | 088331-001 | May 17, 1984 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Mankind Pharma | LIDOCAINE HYDROCHLORIDE | lidocaine hydrochloride | INJECTABLE;INJECTION | 217692-003 | Nov 29, 2023 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for lidocaine hydrochloride
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Powder Pharms | ZINGO | lidocaine hydrochloride | SYSTEM;INTRADERMAL | 022114-001 | Aug 16, 2007 | ⤷ Try a Trial | ⤷ Try a Trial |
| Powder Pharms | ZINGO | lidocaine hydrochloride | SYSTEM;INTRADERMAL | 022114-001 | Aug 16, 2007 | ⤷ Try a Trial | ⤷ Try a Trial |
| Powder Pharms | ZINGO | lidocaine hydrochloride | SYSTEM;INTRADERMAL | 022114-001 | Aug 16, 2007 | ⤷ Try a Trial | ⤷ Try a Trial |
| Powder Pharms | ZINGO | lidocaine hydrochloride | SYSTEM;INTRADERMAL | 022114-001 | Aug 16, 2007 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for lidocaine hydrochloride
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2015222937 | Device for delivering particles | ⤷ Try a Trial |
| Taiwan | 201540331 | Device for delivering particles | ⤷ Try a Trial |
| World Intellectual Property Organization (WIPO) | 2015130961 | ⤷ Try a Trial | |
| Singapore | 11201606034W | DEVICE FOR DELIVERING PARTICLES | ⤷ Try a Trial |
| United Kingdom | 0708758 | ⤷ Try a Trial | |
| World Intellectual Property Organization (WIPO) | 2008135719 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
© Copyright 2002-2024 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Links
Follow DrugPatentWatch:
